Health & Fitness
Health and Fitness
Health and Fitness 
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
DURHAM, N.C.--([ BUSINESS WIRE ])--Trimeris, Inc. (Nasdaq: TRMS) today announced that the Board of Directors has declared a one-time special cash dividend of $1.00 per share of common stock to stockholders of record on December 19, 2008. The aggregate dividend payment will total approximately $22.3 million based on the number of shares of common stock currently outstanding. The dividend will be paid on December 29, 2008. The Company had previously announced its plan to return capital of $50 million to shareholders by the end of 2008. Today's announcement, coupled with the Company's $33.3 million special dividend earlier in the year, will result in the return of over $55 million in capital to shareholders in 2008.
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at [ http://www.trimeris.com ].